|
|
Home > Investor Relations > Financials
> P & L Account
> Ranbaxy Laboratories Limited - Consolidated (Indian GAAP) |
| |
P
& L Account
Untitled Document
| CONSOLIDATED PROFIT
AND LOSS ACCOUNT
FOR THE YEAR ENDED DECEMBER 31, 2006 |
| |
|
Rs. in
Million |
| |
Schedule |
2006 |
2005 |
| INCOME |
|
|
|
| Operating income |
15 |
61,915.78 |
53,676.83 |
| Less excise duty |
|
481.72 |
860.96 |
| |
|
61,434.06 |
52,815.87 |
| Other income |
16 |
564.35 |
616.28 |
| |
|
61,998.41 |
53,432.15 |
| EXPENDITURE |
|
|
|
| Materials |
17 |
23,733.09 |
22,212.71 |
| Manufacturing |
18 |
3,098.76 |
2,549.40 |
| Personnel |
19 |
7,955.29 |
6,785.66 |
| Selling, general and administration |
20 |
13,866.94 |
13,231.94 |
| Research and development |
21 |
3,954.79 |
4,925.07 |
| |
|
52,608.87 |
49,704.78 |
PROFIT BEFORE INTEREST, DEPRECIATION,
AMORTIZATION AND IMPAIRMENT |
|
9,389.54 |
3,727.37 |
| Interest |
|
1,036.32 |
671.16 |
| Depreciation, amortization and impairment |
22 |
1,842.88 |
1,444.52 |
| PROFIT FROM OPERATIONS |
|
|
|
| Continuing operations |
|
6,510.34 |
1,371.22 |
| Discontinued operations |
|
– |
240.47 |
| PROFIT FROM OPERATIONS BEFORE
EXCEPTIONAL ITEMS |
|
6,510.34 |
1,611.69 |
| Interest in Joint venture written off |
|
– |
(121.80) |
| Profit from sale of undertaking and a
subsidiary |
|
– |
454.95 |
| PROFIT BEFORE TAX |
|
6,510.34 |
1,944.84 |
| Provision for tax |
23 |
1,356.74 |
(697.57) |
| PROFIT AFTER TAX |
|
5,153.60 |
2,642.41 |
| Minority interests |
|
50.21 |
25.35 |
| PROFIT AFTER TAX AND MINORITY
INTERESTS |
|
5,103.39 |
2,617.06 |
| Tax - earlier years |
|
148.06 |
(61.78) |
| Balance as per last balance sheet |
|
1,253.94 |
2,532.50 |
| Transfer from Foreign projects reserve |
|
22.95 |
30.65 |
| BALANCE AVAILABLE FOR APPROPRIATION |
|
6,528.34 |
5,118.43 |
| APPROPRIATIONS |
|
|
|
| Dividend |
|
|
|
| Interim |
|
3,168.94 |
931.11 |
| Final (proposed) |
|
– |
2,235.55 |
| Tax on dividend |
|
444.44 |
447.83 |
| Transfer to General reserve |
|
450.00 |
250.00 |
| Surplus carried forward |
|
2,464.96 |
1,253.94 |
| |
|
6,528.34 |
5,118.43 |
| EARNINGS PER SHARE (Rs.) |
24 |
|
|
| Including discontinued operations and
exceptional items |
|
|
|
| Basic |
|
14.09 |
6.87 |
| Diluted |
|
13.17 |
6.84 |
| Excluding discontinued operations and
exceptional items |
|
|
|
| Basic |
|
14.09 |
5.70 |
| Diluted |
|
13.17 |
5.69 |
| SIGNIFICANT ACCOUNTING POLICIES |
25 |
|
|
| NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS |
26 |
|
|
The schedules
referred to above form an integral part of the consolidated financial
statements.
This is the consolidated profit and loss account referred to in
our report of even date. |
| |
On behalf of the Board of Directors
|
For WALKER, CHANDIOK & CO
Chartered Accountants
|
TEJENDRA KHANNA Chairman
|
| VINOD CHANDIOK
Partner
Membership No. 10093
|
DR. BRIAN W. TEMPEST
Chief Mentor &
Executive Vice Chairman
MALVINDER MOHAN SINGH
CEO & Managing Director
|
| |
ATUL SOBTI
Chief Operating Officer &
Whole-time Director
|
| |
RAM S. RAMASUNDAR
President & CFO
|
| Place : Gurgaon
Dated : March 29, 2007
|
SUSHIL K. PATAWARI
Secretary
|
|
|
|